S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:RKDA

Arcadia Biosciences (RKDA) Stock Price, News & Analysis

$2.21
-0.09 (-3.91%)
(As of 03:59 PM ET)
Today's Range
$2.12
$2.30
50-Day Range
$2.25
$3.07
52-Week Range
$2.12
$8.18
Volume
27,167 shs
Average Volume
19,983 shs
Market Capitalization
$2.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Arcadia Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
578.7% Upside
$15.00 Price Target
Short Interest
Healthy
0.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.97mentions of Arcadia Biosciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$1,442 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($8.23) to ($4.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.81 out of 5 stars

RKDA stock logo

About Arcadia Biosciences Stock (NASDAQ:RKDA)

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

RKDA Stock Price History

RKDA Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Arcadia Biosciences, Inc. (RKDA)
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
HYFM Sep 2024 1.000 call
Arcadia Biosciences Inc
Arcadia Biosciences Inc (RKDA)
Arcadia Biosciences Inc RKDA
Q3 2023 Arcadia Biosciences Inc Earnings Call
Q2 2023 Arcadia Biosciences Inc Earnings Call
See More Headlines
Receive RKDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Next Earnings (Confirmed)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Agricultural production - crops
Sub-Industry
N/A
Current Symbol
NASDAQ:RKDA
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$20.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+575.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,380,000.00
Net Margins
-279.74%
Pretax Margin
-290.32%

Debt

Sales & Book Value

Annual Sales
$9.96 million
Book Value
$33.92 per share

Miscellaneous

Free Float
1,088,000
Market Cap
$2.46 million
Optionable
Not Optionable
Beta
0.62
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

RKDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcadia Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings
or view top-rated stocks.

What is Arcadia Biosciences' stock price target for 2024?

1 analysts have issued twelve-month price objectives for Arcadia Biosciences' stock. Their RKDA share price targets range from $10.00 to $20.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 578.7% from the stock's current price.
View analysts price targets for RKDA
or view top-rated stocks among Wall Street analysts.

How have RKDA shares performed in 2024?

Arcadia Biosciences' stock was trading at $3.13 at the beginning of 2024. Since then, RKDA shares have decreased by 29.4% and is now trading at $2.21.
View the best growth stocks for 2024 here
.

When is Arcadia Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our RKDA earnings forecast
.

How can I listen to Arcadia Biosciences' earnings call?

Arcadia Biosciences will be holding an earnings conference call on Thursday, March 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) posted its quarterly earnings results on Monday, November, 15th. The basic materials company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.13. The basic materials company had revenue of $2.38 million for the quarter, compared to the consensus estimate of $2.73 million. Arcadia Biosciences had a negative net margin of 279.74% and a negative trailing twelve-month return on equity of 77.09%. During the same period in the prior year, the firm posted ($0.54) earnings per share.

When did Arcadia Biosciences' stock split?

Shares of Arcadia Biosciences reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Arcadia Biosciences IPO?

Arcadia Biosciences (RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

Who are Arcadia Biosciences' major shareholders?

Arcadia Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.26%), Vanguard Group Inc. (1.26%), Virtu Financial LLC (1.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Pamela Haley, Stanley Jacot Jr and Thomas J Schaefer.
View institutional ownership trends
.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RKDA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners